Loading patent…
AssigneeAdelaide Research & Innovation Pty Ltd
InventorsShaun Reuss McColl, Ian Comerford, Yuka Harata-Lee, Mark Smyth
Estimating the term…
The present invention provides a catalyst precursor and a catalyst suitable for preparing multi-wall carbon nanotubes. The resulting multi-wall carbon nanotubes have a narrow distribution as to the number of walls forming the tubes and a narrow distribution in the range of diameters for the tubes. Additionally, the present invention provides methods for producing multi-wall carbon nanotubes having narrow distributions in the number of walls and diameters. Further, the present invention provides a composition of spent catalyst carrying multi-wall nanotubes having narrow distribution ranges of walls and diameters.
A method of inducing an immune response to a cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of a chemokine receptor CCX-CKR.
The method according to claim 27, wherein the cancer is a metastatic cancer.
The method according to claim 27, wherein the inhibitor comprises one or more of a small interfering RNA, a microRNA, an antisense RNA, a ligand for a chemokine receptor CCX-CKR, and an antibody and/or an antigen binding part thereof.
The method according to claim 27, wherein administering the inhibitor to the subject induces anti-tumour CD4+ and/or CD8+ cells in the subject.
An antibody to a chemokine receptor CCX-CKR and/or an antigen binding part thereof, wherein the antibody and/or the antigen binding part thereof inhibits metastasis of a cancer in a subject.
The antibody and/or antigen binding part thereof according to claim 29, wherein the cancer is a melanoma, a breast cancer, a prostate cancer, an ovarian cancer, or a colorectal cancer.
The antibody and/or antigen binding part thereof according to claim 29, wherein the antibody and/or the antigen binding part thereof binds to one or more amino acids and/or an epitope located in one or more of the following regions of the human chemokine receptor CCX-CKR:
A cell expressing an antibody and/or antigen binding part thereof according to claim
A method of preventing and/or treating metastatic cancer in a subject, the method comprising administering to the subject an effective amount of an antibody and/or an antigen binding part thereof according to claim 29.
The antibody and/or antigen binding part thereof according to claim 33, wherein the antibody and/or the antigen binding part thereof binds to one or more amino acids and/or an epitope located in amino acids 1 to 42 of the human chemokine receptor CCX-CKR.
The antibody and/or antigen binding part thereof according to claim 68, wherein the antibody and/or the antigen binding part thereof binds to an one or more amino acids and/or an epitope in one or more of polypeptide sequences:
The antibody and/or antigen binding part thereof according to claim 29, wherein administering the antibody and/or antigen binding part thereof to the subject induces anti-tumour CD4+ and/or CD8+ cells in the subject.
Dependencies are inferred from the claim text.